Protalix Biotherapeutics is a biopharmaceutical company dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles produced with their proprietary ProCellEx® plant cell-based expression system. They focus on developing and commercializing drugs, such as pegunigalsidase alfa for the treatment of Fabry disease and alidornase alfa for respiratory diseases, using their technology platform which allows for oral delivery of proteins. The company has completed enrollment for all its clinical studies and seeks collaborations to expand its pipeline or develop new therapeutic proteins.